JP2003055199A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003055199A5 JP2003055199A5 JP2001248426A JP2001248426A JP2003055199A5 JP 2003055199 A5 JP2003055199 A5 JP 2003055199A5 JP 2001248426 A JP2001248426 A JP 2001248426A JP 2001248426 A JP2001248426 A JP 2001248426A JP 2003055199 A5 JP2003055199 A5 JP 2003055199A5
- Authority
- JP
- Japan
- Prior art keywords
- release
- sustained
- water
- spray
- morphine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 16
- 238000013268 sustained release Methods 0.000 description 16
- 239000012730 sustained-release form Substances 0.000 description 16
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 239000007921 spray Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 229960005181 morphine Drugs 0.000 description 8
- 229960004715 morphine sulfate Drugs 0.000 description 8
- 239000001856 Ethyl cellulose Substances 0.000 description 7
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 7
- 229920001249 ethyl cellulose Polymers 0.000 description 7
- 235000019325 ethyl cellulose Nutrition 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- -1 aminoalkyl methacrylate Chemical compound 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 229940089053 kadian Drugs 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- 229920003176 water-insoluble polymer Polymers 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003405 delayed action preparation Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 239000001069 triethyl citrate Substances 0.000 description 4
- 235000013769 triethyl citrate Nutrition 0.000 description 4
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 241000917703 Leia Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940089530 ms contin Drugs 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001248426A JP4848101B2 (ja) | 2001-08-17 | 2001-08-17 | 徐放性マイクロペレット |
| PCT/JP2002/008245 WO2003015758A1 (en) | 2001-08-17 | 2002-08-12 | Sustained release micropellets and process for producing the same |
| ES02760617T ES2375624T3 (es) | 2001-08-17 | 2002-08-12 | Microgranulados de liberación controlada y procedimiento para su producción. |
| AU2002327085A AU2002327085B9 (en) | 2001-08-17 | 2002-08-12 | Sustained release micropellets and process for producing the same |
| US10/486,898 US20040208930A1 (en) | 2001-08-17 | 2002-08-12 | Sustained release micropellets and process for producing the same |
| AT02760617T ATE531360T1 (de) | 2001-08-17 | 2002-08-12 | Mikrokügelchen mit verzögerter freisetzung und verfahren zu ihrer herstellung |
| DK02760617.7T DK1417960T3 (da) | 2001-08-17 | 2002-08-12 | Mikropellets med vedvarende frisætning og fremgangsmåde til fremstilling heraf |
| EP02760617A EP1417960B1 (en) | 2001-08-17 | 2002-08-12 | Sustained release micropellets and process for producing the same |
| CA2459472A CA2459472C (en) | 2001-08-17 | 2002-08-12 | Sustained release micropellets and process for producing the same |
| US11/889,744 US8512744B2 (en) | 2001-08-17 | 2007-08-16 | Sustained release micropellets and process for producing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001248426A JP4848101B2 (ja) | 2001-08-17 | 2001-08-17 | 徐放性マイクロペレット |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003055199A JP2003055199A (ja) | 2003-02-26 |
| JP2003055199A5 true JP2003055199A5 (enExample) | 2008-10-16 |
| JP4848101B2 JP4848101B2 (ja) | 2011-12-28 |
Family
ID=19077585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001248426A Expired - Lifetime JP4848101B2 (ja) | 2001-08-17 | 2001-08-17 | 徐放性マイクロペレット |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20040208930A1 (enExample) |
| EP (1) | EP1417960B1 (enExample) |
| JP (1) | JP4848101B2 (enExample) |
| AT (1) | ATE531360T1 (enExample) |
| AU (1) | AU2002327085B9 (enExample) |
| CA (1) | CA2459472C (enExample) |
| DK (1) | DK1417960T3 (enExample) |
| ES (1) | ES2375624T3 (enExample) |
| WO (1) | WO2003015758A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| WO2001032148A1 (en) | 1999-10-29 | 2001-05-10 | Euro-Celtique, S.A. | Controlled release hydrocodone formulations |
| CN101317825A (zh) | 2000-10-30 | 2008-12-10 | 欧罗赛铁克股份有限公司 | 控释氢可酮制剂 |
| EP1663469A4 (en) | 2003-09-05 | 2009-01-07 | Univ Massachusetts | AMPHIPHILIC POLYMER CAPSULES AND ASSOCIATED METHODS OF INTERFACIAL ASSEMBLY |
| ES2390879T3 (es) * | 2003-12-31 | 2012-11-19 | Actavis Group Ptc Ehf. | Formulaciones de atomoxetina |
| EP1796621B2 (en) * | 2004-10-01 | 2014-04-09 | Firmenich Sa | Perfuming or flavouring microcapsules comprising an explosion suppressant |
| US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
| KR100866720B1 (ko) | 2004-12-27 | 2008-11-05 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 항치매 약물의 안정화 방법 |
| KR101213345B1 (ko) * | 2005-04-28 | 2012-12-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 항치매약을 함유하는 조성물 |
| US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
| US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
| MX2012012991A (es) | 2010-05-11 | 2012-11-30 | Cima Labs Inc | Formas de dosificacion oral de liberacion prolongada resistentes al alcohol y que contienen metoprolol. |
| CA3246974A1 (en) * | 2022-04-01 | 2023-10-05 | Emplicure Ab Publ | ALKALINE INTRAORAL PRODUCTS |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6058890B2 (ja) * | 1978-10-20 | 1985-12-23 | 東洋醸造株式会社 | 抗生物質細粒剤の製造法およびそれを用いる複粒剤 |
| JPS583510A (ja) * | 1981-06-29 | 1983-01-10 | 住友電気工業株式会社 | 海底ケ−ブル等の埋設機の積卸方法 |
| JPS5835110A (ja) * | 1981-08-28 | 1983-03-01 | Tetsuo Kato | 徐放性マイクロカプセル |
| JPS5944311A (ja) * | 1982-09-07 | 1984-03-12 | Santen Pharmaceut Co Ltd | 徐放性顆粒およびその製造法 |
| GB2150434B (en) * | 1983-12-01 | 1987-11-04 | Alza Corp | Constant rate release systems |
| US4777049A (en) * | 1983-12-01 | 1988-10-11 | Alza Corporation | Constant release system with pulsed release |
| DK62184D0 (da) * | 1984-02-10 | 1984-02-10 | Benzon As Alfred | Diffusionsovertrukket polydepotpraeparat |
| US4753802A (en) * | 1986-03-19 | 1988-06-28 | Alza Corporation | Verapamil dosage form |
| US5026560A (en) * | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
| JPH0832625B2 (ja) * | 1987-01-29 | 1996-03-29 | 武田薬品工業株式会社 | 有核顆粒およびその製造法 |
| US4931285A (en) * | 1988-04-28 | 1990-06-05 | Alza Corporation | Aqueous based pharmaceutical coating composition for dosage forms |
| US5202128A (en) * | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
| HU205851B (en) * | 1989-01-31 | 1992-07-28 | Int Pharma Agentur | Systhem of regulated release of the active components and process for producing it |
| JP2820829B2 (ja) * | 1991-03-07 | 1998-11-05 | 武田薬品工業株式会社 | 有核散剤およびその製造方法 |
| US5229135A (en) * | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
| IT1264020B (it) * | 1993-01-28 | 1996-09-09 | Recordati Chem Pharm | Procedimento per la preparazione di microgranuli idonei alla sospensione in liquidi |
| WO1995003052A1 (en) * | 1993-07-22 | 1995-02-02 | Warner-Lambert Company | Controlled release tacrine drug delivery systems and methods for preparing same |
| JPH0789849A (ja) * | 1993-09-20 | 1995-04-04 | Fujisawa Pharmaceut Co Ltd | 徐放性製剤 |
| US6077533A (en) * | 1994-05-25 | 2000-06-20 | Purdue Pharma L.P. | Powder-layered oral dosage forms |
| US5411745A (en) * | 1994-05-25 | 1995-05-02 | Euro-Celtique, S.A. | Powder-layered morphine sulfate formulations |
| JPH10139659A (ja) * | 1996-09-10 | 1998-05-26 | Freunt Ind Co Ltd | 球形粒子群、その製造方法及びそれを用いた球形粒子製剤 |
| TW477702B (en) * | 1997-10-23 | 2002-03-01 | Dev Center Biotechnology | Controlled release tacrine dosage form |
| SE9704869D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
| FR2794646B1 (fr) * | 1999-06-09 | 2001-09-21 | Ethypharm Lab Prod Ethiques | Microgranules de sulfate de morphine, procede de preparation et composition les contenant |
-
2001
- 2001-08-17 JP JP2001248426A patent/JP4848101B2/ja not_active Expired - Lifetime
-
2002
- 2002-08-12 US US10/486,898 patent/US20040208930A1/en not_active Abandoned
- 2002-08-12 EP EP02760617A patent/EP1417960B1/en not_active Expired - Lifetime
- 2002-08-12 AT AT02760617T patent/ATE531360T1/de active
- 2002-08-12 DK DK02760617.7T patent/DK1417960T3/da active
- 2002-08-12 ES ES02760617T patent/ES2375624T3/es not_active Expired - Lifetime
- 2002-08-12 WO PCT/JP2002/008245 patent/WO2003015758A1/ja not_active Ceased
- 2002-08-12 AU AU2002327085A patent/AU2002327085B9/en not_active Ceased
- 2002-08-12 CA CA2459472A patent/CA2459472C/en not_active Expired - Fee Related
-
2007
- 2007-08-16 US US11/889,744 patent/US8512744B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2022640C (en) | Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets | |
| CN1886119B (zh) | 泮托拉唑多颗粒制剂 | |
| US5824339A (en) | Effervescent composition and its production | |
| EP0523847B1 (en) | Taste mask coating for preparation of chewable pharmaceutical tablets | |
| US5260072A (en) | Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets | |
| CA2063141C (en) | Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets | |
| JP2005506323A (ja) | 経口送達用機能性散剤 | |
| JP2006502156A (ja) | 風味を遮断された投与形態およびそれらの製剤の方法 | |
| JP2003055199A5 (enExample) | ||
| JP5046946B2 (ja) | 低乱用性薬学的製剤 | |
| JP4848101B2 (ja) | 徐放性マイクロペレット | |
| CA2684586A1 (en) | High dose composition of ursodeoxycholic acid | |
| HUT52369A (en) | New form of mediacament | |
| JP3221891B2 (ja) | 咀嚼可能な製薬錠剤調製のための回転造粒及び味覚遮蔽被覆加工 | |
| US5460825A (en) | Taste mask coatings for preparing chewable pharmaceutical tablets | |
| EP0538034A1 (en) | Taste mask coatings for preparing chewable pharmaceutical tablets | |
| CN102579398A (zh) | 一种具有掩盖药物不良口味作用的肠溶微囊及制备方法 | |
| JP4716063B2 (ja) | 不快味マスキング粒子及びこれを含有する経口製剤 | |
| ES2516693T3 (es) | Esferoides farmacéuticos | |
| JP2003306428A (ja) | 服用性を改善した硬カプセル剤 | |
| JP3505734B2 (ja) | エカベトナトリウム含有経口投与用製剤 | |
| JPS61148114A (ja) | ニフエジピンの顆粒剤 | |
| JP7534139B2 (ja) | 動物用医薬製剤 | |
| JPH02193914A (ja) | マトリックス型持続性製剤 |